Logo image
The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity
Journal article   Open access   Peer reviewed

The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity

Leah R Reznikov, David K Meyerholz, Mahmoud Abou Alaiwa, Shin-Ping Kuan, Yan-Shin J Liao, Nicholas L Bormann, Thomas B Bair, Margaret Price, David A Stoltz and Michael J Welsh
American journal of physiology. Lung cellular and molecular physiology, Vol.315(2), pp.L133-L148
Translational Physiology
08/01/2018
DOI: 10.1152/ajplung.00557.2017
PMCID: PMC6139658
PMID: 29631359
url
https://doi.org/10.1152/ajplung.00557.2017View
Published (Version of record) Open Access

Abstract

Mainstay therapeutics are ineffective in some people with asthma, suggesting a need for additional agents. In the current study, we used vagal ganglia transcriptome profiling and connectivity mapping to identify compounds beneficial for alleviating airway hyperreactivity (AHR). As a comparison, we also used previously published transcriptome data from sensitized mouse lungs and human asthmatic endobronchial biopsies. All transcriptomes revealed agents beneficial for mitigating AHR; however, only the vagal ganglia transcriptome identified agents used clinically to treat asthma (flunisolide, isoetarine). We also tested one compound identified by vagal ganglia transcriptome profiling that had not previously been linked to asthma and found that it had bronchodilator effects in both mouse and pig airways. These data suggest that transcriptome profiling of the vagal ganglia might be a novel strategy to identify potential asthma therapeutics.
airway hyperreactivity therapeutics asthma transcriptome sequencing neurons vagus

Details

Metrics

Logo image